Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCL’s Novel Approach to Research in Biologically-Relevant Models

Published: Wednesday, March 19, 2014
Last Updated: Tuesday, March 18, 2014
Bookmark and Share
Cellectricon and UCL unite to present a webinar, March 27, 11am-12pm EDT.

Cellectricon will co-host a webinar with top researchers at University College London (UCL). The webinar will explore the use of primary cells as a biologically-relevant model for biomedical research, and highlight the new high-throughput techniques and phenotypic screening approaches that are used by UCL to investigate cellular processes in such cells.

The paradigm shift which proposes the use of primary cell types, rather than traditional transformed cell lines, provides a more physiologically accurate view and could help reduce the current high attrition rate in drug discovery programmes.

Offering participants a rare opportunity to hear first-hand from leading researchers, the webinar, entitled ‘Novel approaches for the study of cellular processes in biologically-relevant model systems’, will take place on March 27, 11am-12pm EDT.

To register, please visit www.cellecticon.com/events.

Participants will hear from Dr Robin Ketteler, Group Leader, and Dr Catia Andreassi, Senior Scientist, at the MRC Laboratory for Molecular Cell Biology, UCL, who will provide listeners with an expert insight into the mechanisms of axonal mRNA transport, a vital process for the maintenance of precise neuronal networks in the brain.

The session will go on to reveal how Dr Ketteler’s team are using combinatorial approaches to investigate cellular regulation mechanisms in primary neurons, and how these methods have enabled the group to identify a novel regulatory element that directs mRNA localization and translation.

Attendees of this webinar will gain an educational and eye-opening overview of new techniques that can be used successfully to drive biomedical research in biologically-relevant models.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellectricon, Neurexpert Announce Collaboration
Cellectricon and Neurexpert will co-promote their combined CNS drug discovery expertise, with a particular focus on synaptic function assays, for research into treatments of central nervous system disorders in the fields of psychiatry, neurology, pain and neurodegeneration.
Wednesday, June 08, 2016
Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services
The company, a leading provider of advanced cell-based discovery services, has appointed Dr Edwin Johnson, Director of The Stockholm Brain Institute, as the first member of its new Scientific Advisory Board.
Thursday, July 09, 2015
Cellectricon Announces Project Grant Winners
The grant was awarded for project proposals utilizing Cellectricon’s Cellaxess ACE technology for the delivery of non-genetic material to adherent cells and cultures.
Thursday, September 19, 2013
Presenting Phenotypic Screening Strategies for Chronic Pain Research
Cellectricon explores novel phenotypic assay designs in a webinar, 5 September, 11am-12pm (EDT).
Wednesday, August 21, 2013
Cellectricon Launches Grant to Fund Electroporation-based Research
New Cellaxess® Project Grant supports advanced research projects.
Wednesday, July 10, 2013
Dr. Paul Karila appointed Head of Discovery Services at Cellectricon AB
Discovery services will be based on automated cellular electric field manipulation for novel screening applications.
Wednesday, June 13, 2012
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!